Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.
作者信息
Kishi Taro, Iwama Yasuhiro, Sasagawa Yuji, Hiraoka Shuichi, Kamei Aya, Iwata Nakao
机构信息
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.
Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
出版信息
Psychiatry Clin Neurosci. 2023 Jun;77(6):365-366. doi: 10.1111/pcn.13540. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
Asenapine add-on treatment for schizophrenia adults who received antipsychotics: A 52-week, open-label study.阿塞那平对接受抗精神病药物治疗的成年精神分裂症患者的附加治疗：一项为期52周的开放标签研究。
Psychiatry Clin Neurosci. 2023 Jun;77(6):365-366. doi: 10.1111/pcn.13540. Epub 2023 Mar 17.
2
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.早期个体症状的改善可预测精神分裂症患者使用阿塞那平治疗的反应。
Neuropsychopharmacol Rep. 2020 Jun;40(2):138-149. doi: 10.1002/npr2.12103. Epub 2020 Mar 16.
3
Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.HP-3070（阿塞那平透皮贴剂）治疗精神分裂症的疗效和安全性：一项 3 期、随机、安慰剂对照研究。
J Clin Psychiatry. 2020 Dec 15;82(1):20m13602. doi: 10.4088/JCP.20m13602.
4
Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.阿塞那平治疗亚洲精神分裂症急性加重患者的疗效与安全性：一项多中心、随机、双盲、为期6周的安慰剂对照研究。
Psychopharmacology (Berl). 2016 Jul;233(14):2663-74. doi: 10.1007/s00213-016-4295-9. Epub 2016 Jun 8.
5
Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.阿塞那平治疗精神分裂症患者疗效的最佳剂量：真实世界数据
Neuropsychopharmacol Rep. 2024 Mar;44(1):234-239. doi: 10.1002/npr2.12389. Epub 2023 Nov 5.
6
Asenapine versus placebo for schizophrenia.阿塞那平与安慰剂治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2015 Nov 24;2015(11):CD011458. doi: 10.1002/14651858.CD011458.pub2.
7
Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
Psychopharmacol Bull. 1976 Jan;12(1):31-4.
8
Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.阿塞那平治疗青少年精神分裂症8周双盲试验及26周开放标签延长期的安全性和有效性
J Child Adolesc Psychopharmacol. 2015 Jun;25(5):384-96. doi: 10.1089/cap.2015.0027.
9
Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.阿塞那平治疗精神分裂症和双相情感障碍：这种新批准的舌下吸收第二代抗精神病药物的疗效和安全性概况综述。
Int J Clin Pract. 2009 Dec;63(12):1762-84. doi: 10.1111/j.1742-1241.2009.02228.x. Epub 2009 Oct 14.
10
Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.阿塞那平与布雷哌唑治疗老年精神分裂症患者的持续治疗率。
Psychogeriatrics. 2021 Nov;21(6):950-951. doi: 10.1111/psyg.12760. Epub 2021 Sep 5.
引用本文的文献
1
Research progress in estrogen as an adjunctive therapy for schizophrenia.雌激素作为精神分裂症辅助治疗的研究进展
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Nov 28;49(11):1849-1860. doi: 10.11817/j.issn.1672-7347.2024.240289.
2
Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.单次给予 D-山梨醇预处理对阿塞那平苦味和持续意愿的影响：一项随机、单盲、安慰剂对照、交叉试验。
BMC Psychiatry. 2024 Jan 30;24(1):81. doi: 10.1186/s12888-024-05549-x.
本文引用的文献
1
Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication.阿塞那平舌下片治疗精神分裂症的长期安全性和疗效：一项为期 52 周（P06125）的 III 期扩展研究及随访的二次发表。
Neuropsychopharmacol Rep. 2023 Sep;43(3):328-337. doi: 10.1002/npr2.12342. Epub 2023 May 25.
2
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.双相情感障碍躁狂症的药物治疗：双盲随机对照试验的系统评价和网络荟萃分析。
Mol Psychiatry. 2022 Feb;27(2):1136-1144. doi: 10.1038/s41380-021-01334-4. Epub 2021 Oct 12.
3
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.32 种口服抗精神病药治疗反复发作性精神分裂症成人患者的急性疗效和耐受性的比较：系统评价和网络荟萃分析。
Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11.
4
Safety and tolerability of antipsychotic polypharmacy.抗精神病药联合用药的安全性和耐受性。
Expert Opin Drug Saf. 2012 Jul;11(4):527-42. doi: 10.1517/14740338.2012.683523. Epub 2012 May 8.
5
The positive and negative syndrome scale (PANSS) for schizophrenia.精神分裂症的阳性与阴性症状量表（PANSS）
Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
Zotero 插件